Overview

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Status:
Recruiting
Trial end date:
2029-01-31
Target enrollment:
Participant gender:
Summary
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Phase:
Phase 2
Details
Lead Sponsor:
IDEAYA Biosciences